克服药物障碍的新型小分子疟疾药物的临床前开发-猫眼课题宝

克服药物障碍的新型小分子疟疾药物的临床前开发

批准号：

8837558

负责人：

DAVID H PEYTON

金额：

$99.97万

依托单位：

DESIGNMEDIX, INC.

依托单位国家：

美国

项目类别：

财政年份：

2011

资助国家：

美国

项目状态：

已结题

起止时间：

2011-09-01 至 2017-03-31

来源：

https://reporter.nih.gov/project-details/8837558

关键词：

Abbreviations Antimalarials Artemisinins Award Back Carrier Proteins Child Chloroquine Chloroquine resistance Clinical Research Clinical Trials Combined Modality Therapy Development Disease Dose Drug Kinetics Drug resistance Ethers Evaluation Failure Funding Gene Proteins Goals Gold Health Human Hybrids In Vitro Inhibitory Concentration 50 Institutes Intravenous Investigational Drugs Lead Lethal Dose 50 Link Malaria Monkeys Multi-Drug Resistance Mutate Neuraxis Oral Parasites Pathway interactions Pharmaceutical Preparations Pharmacodynamics Pharmacologic Substance Pharmacology Phase Plasmodium falciparum Positioning Attribute Preclinical Drug Development Preclinical Testing Predisposition Pregnant Women Property Rattus Research Contracts Resistance Small Business Technology Transfer Research Staging Structure-Activity Relationship Toxic effect Tropical Disease Universities Vacuole Verapamil artemisinine base chemosensitizing agent design drug candidate drug development flexibility forgetting in vivo innovation killings novel pre-clinical preclinical evaluation preclinical study research clinical testing resistant strain response small molecule trait vaccine development

项目摘要

项目成果

DAVID H PEYTON的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine-resistant and chloroquine-sensitive malaria. This project carries on preclinical development of a drug candidate that has been selected from this innovative class of potent antimalarials designed to overcome drug resistance. The candidate will be advanced through the ultimate stages of preclinical testing. Thus, pharmacokinetics, pharmacodynamics, pharmacology, and toxicity evaluations will be performed in both rats and monkeys. The overall goal will be completion of preclinical studies leading to approval of an Investigative New Drug (IND) application for the drug to be used in a Phase 1 human clinical trial.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文